Skip to content

ImmunityBio

US · IBRX #1397 by market cap Listed 1970
6.02 -0.55 -8.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Recent news

  • Rating change
    H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/2/19
  • Rating change
    Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $12
    Market Newswire · 2026/3/4
  • A Quick Look at Today's Ratings for ImmunityBio(IBRX.US), With a Forecast Between $12 to $16
    Market Newswire · 2026/10/15
  • Earnings Flash (IBRX) ImmunityBio Posts Q3 Net Loss $0.18 a Share, Vs. FactSet Est of $0.07 Loss
    MT Newswires · 2026/11/9
  • BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/11/10
  • Rating change
    BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $13
    Market Newswire · 2026/3/12
  • Rating change
    Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $5
    Market Newswire · 2025/12/15
  • Rating change
    BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $9
    Market Newswire · 2026/1/23
  • Rating change
    BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $9
    Market Newswire · 2026/2/3
  • Rating change
    H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $10
    Market Newswire · 2026/1/26
  • Rating change
    BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Cuts Target Price to $12
    Market Newswire · 2026/5/8
  • Rating change
    Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/9/8
  • Rating change
    BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $13
    Market Newswire · 2026/3/25
  • Rating change
    ImmunityBio (IBRX) Receives a Buy From H.C. Wainwright
    TipRanks · 2026/5/8
  • H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $15
    Market Newswire · 2026/11/10
  • Rating change
    H.C. Wainwright Sticks to Its Buy Rating for ImmunityBio (IBRX)
    TipRanks · 2026/4/30
  • Rating change
    Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $7
    Market Newswire · 2026/1/20
  • Divergence in Insider Trading Among U.S. Biotech Stocks: ImmunityBio (IBRX.US) Sees Largest Cash-Out, While Sellas (SLS.US) Directors Buy In Before 5-Fold Surge
    Zhitong Finance · 2026/11/12
  • Rating change
    H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $15
    Market Newswire · 2026/2/24
  • Rating change
    H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $8
    Market Newswire · 2026/1/20
  • Form 144 | ImmunityBio(IBRX.US) Officer Proposes to Sell 7.66 Million in Common Stocks
    Market Newswire · 2026/10/5
  • H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $15
    Market Newswire · 2026/10/15
  • Rating change
    Jefferies Initiates ImmunityBio(IBRX.US) With Buy Rating, Announces Target Price $9
    Market Newswire · 2025/12/13
  • BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/10/30
  • BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/8/5

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:59:40 · For reference only, not investment advice and not tailored to your situation.

ImmunityBio discussion 0 comments

Add a comment